Novira Therapeutics

About:

Novira Therapeutics is an antiviral drug discovery company discovering antiviral therapeutics to treat HBV and HIV infections.

Website: http://www.noviratherapeutics.com

Top Investors: BioAdvance, 5AM Ventures, Versant Ventures, Canaan Partners, Robin Hood Ventures

Description:

Novira Therapeutics is an antiviral drug discovery company that is focused on the discovery of first-in-class antiviral therapeutics for the treatment of chronic HBV and HIV infections, two global diseases with high levels of unmet need. Novira’s oral drugs target the capsid of the virus, and offer a promising treatment option both as monotherapy and in combination with current standards of care. The company’s antivirals potentially address limitations in treating chronic HBV infection, a disease for which the only class of oral drugs available, polymerase inhibitors, are rarely curative and often require lifelong treatment, as well as in chronic HIV infection, a disease for which the continued ability of the virus to mutate inevitably leads to drug-resistant viral strains. Each of these limitations to the standard of care can potentially be addressed by capsid inhibitors which feature a new mechanism of action.

Total Funding Amount:

$39.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Radnor, Pennsylvania, United States

Founded Date:

2009-01-01

Contact Email:

info(AT)noviratherapeutics.com

Founders:

Ali Munawar, George Hartman, Osvaldo Flores

Number of Employees:

11-50

Last Funding Date:

2014-12-24

IPO Status:

Private

Industries:

© 2025 bioDAO.ai